Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes

Jeffrey W. Meeusen; Leslie J. Donato; Allan S. Jaffe

doi:10.1007/s11886-017-0863-9

Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes

Jeffrey W. Meeusen, Leslie J. Donato, Allan S. Jaffe

Cardiovascular Medicine

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Purpose of Review: The objective of this review was to summarize evidence gathered for the prognostic value of routine and novel blood lipids and lipoproteins measured in patients with acute coronary syndromes (ACS). Recent Findings: Data supports clear association with risk and actionable value for non-high-density lipoprotein (Non-HDL) cholesterol and plasma ceramides in a setting of ACS. The prognostic value and clinical actionability of apolipoprotein B (apoB) and lipoprotein(a) [Lp(a)] in ACS have not been thoroughly tested, while the data for omega-3 fatty acids and oxidized low-density lipoprotein (Ox-LDL) are either untested or more varied. Summary: Measuring basic lipids, which should include Non-HDL cholesterol, at the time of presentation for ACS is guideline mandated. Plasma ceramides also provide useful information to guide both treatment decisions and follow-up. Additional studies targeting ACS patients are necessary for apoB, Lp(a), omega-3 fatty acids, and Ox-LDL.

Original language	English (US)
Article number	48
Journal	Current cardiology reports
Volume	19
Issue number	6
DOIs	https://doi.org/10.1007/s11886-017-0863-9
State	Published - Jun 1 2017

Keywords

Apolipoprotein B
Ceramides
Lipoprotein(a)
Non-HDL cholesterol
Omega-3
Oxidized LDL

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s11886-017-0863-9

Cite this

@article{48c446f438614ee6bcbf580f4ca5030d,

title = "Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes",

abstract = "Purpose of Review: The objective of this review was to summarize evidence gathered for the prognostic value of routine and novel blood lipids and lipoproteins measured in patients with acute coronary syndromes (ACS). Recent Findings: Data supports clear association with risk and actionable value for non-high-density lipoprotein (Non-HDL) cholesterol and plasma ceramides in a setting of ACS. The prognostic value and clinical actionability of apolipoprotein B (apoB) and lipoprotein(a) [Lp(a)] in ACS have not been thoroughly tested, while the data for omega-3 fatty acids and oxidized low-density lipoprotein (Ox-LDL) are either untested or more varied. Summary: Measuring basic lipids, which should include Non-HDL cholesterol, at the time of presentation for ACS is guideline mandated. Plasma ceramides also provide useful information to guide both treatment decisions and follow-up. Additional studies targeting ACS patients are necessary for apoB, Lp(a), omega-3 fatty acids, and Ox-LDL.",

keywords = "Apolipoprotein B, Ceramides, Lipoprotein(a), Non-HDL cholesterol, Omega-3, Oxidized LDL",

author = "Meeusen, {Jeffrey W.} and Donato, {Leslie J.} and Jaffe, {Allan S.}",

note = "Publisher Copyright: {\textcopyright} 2017, Springer Science+Business Media New York.",

year = "2017",

month = jun,

day = "1",

doi = "10.1007/s11886-017-0863-9",

language = "English (US)",

volume = "19",

journal = "Current cardiology reports",

issn = "1523-3782",

publisher = "Current Medicine Group",

number = "6",

}

TY - JOUR

T1 - Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes

AU - Meeusen, Jeffrey W.

AU - Donato, Leslie J.

AU - Jaffe, Allan S.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Purpose of Review: The objective of this review was to summarize evidence gathered for the prognostic value of routine and novel blood lipids and lipoproteins measured in patients with acute coronary syndromes (ACS). Recent Findings: Data supports clear association with risk and actionable value for non-high-density lipoprotein (Non-HDL) cholesterol and plasma ceramides in a setting of ACS. The prognostic value and clinical actionability of apolipoprotein B (apoB) and lipoprotein(a) [Lp(a)] in ACS have not been thoroughly tested, while the data for omega-3 fatty acids and oxidized low-density lipoprotein (Ox-LDL) are either untested or more varied. Summary: Measuring basic lipids, which should include Non-HDL cholesterol, at the time of presentation for ACS is guideline mandated. Plasma ceramides also provide useful information to guide both treatment decisions and follow-up. Additional studies targeting ACS patients are necessary for apoB, Lp(a), omega-3 fatty acids, and Ox-LDL.

AB - Purpose of Review: The objective of this review was to summarize evidence gathered for the prognostic value of routine and novel blood lipids and lipoproteins measured in patients with acute coronary syndromes (ACS). Recent Findings: Data supports clear association with risk and actionable value for non-high-density lipoprotein (Non-HDL) cholesterol and plasma ceramides in a setting of ACS. The prognostic value and clinical actionability of apolipoprotein B (apoB) and lipoprotein(a) [Lp(a)] in ACS have not been thoroughly tested, while the data for omega-3 fatty acids and oxidized low-density lipoprotein (Ox-LDL) are either untested or more varied. Summary: Measuring basic lipids, which should include Non-HDL cholesterol, at the time of presentation for ACS is guideline mandated. Plasma ceramides also provide useful information to guide both treatment decisions and follow-up. Additional studies targeting ACS patients are necessary for apoB, Lp(a), omega-3 fatty acids, and Ox-LDL.

KW - Apolipoprotein B

KW - Ceramides

KW - Lipoprotein(a)

KW - Non-HDL cholesterol

KW - Omega-3

KW - Oxidized LDL

UR - http://www.scopus.com/inward/record.url?scp=85018478407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018478407&partnerID=8YFLogxK

U2 - 10.1007/s11886-017-0863-9

DO - 10.1007/s11886-017-0863-9

M3 - Review article

C2 - 28432661

AN - SCOPUS:85018478407

SN - 1523-3782

VL - 19

JO - Current cardiology reports

JF - Current cardiology reports

IS - 6

M1 - 48

ER -

Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this